Kyverna Therapeutics

About Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies to liberate patients suffering from autoimmune diseases through the curative potential of cell therapy. Their mission is to achieve long-term remission by resetting the immune system.

Products & Services

KYV-101:A lead CAR T-cell therapy candidate in clinical development for autoimmune diseases in rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, and Phase 1/2 trials for lupus nephritis and systemic sclerosis.

KYV-102:An autologous CAR T-cell therapy in development for B cell-driven autoimmune diseases.

Specialties

Cell Therapy CAR T-Cell Therapy Autoimmune Diseases B Cell-Driven Diseases Clinical Trials in Rheumatology and Neurology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2025-12-17 FD: 2025-12-17	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: 100,000,000 FAN: 100000000	D: 2025-12-15 FD: 2025-12-15	4 investors
3	RT: Debt T: - FT: Debt	A: 150000000 MR: - FA: 150 million FAN: 150000000	D: 2025-11-03 FD: 2025-11-03	1 investors
4	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 366900000 MR: - FA: $366.9 million FAN: 366900000	D: 2024-02-12 FD: 2024-02-12	4 investors
5	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 319000000 MR: - FA: $319.0 million FAN: 319000000	D: 2024-02-07 FD: 2024-02-07	4 investors
6	RT: Series B extension T: - FT: Series B extension	A: 60000000 MR: - FA: $60 million FAN: 60000000	D: 2023-08-15 FD: 2023-08-15	11 investors
7	RT: Series B T: - FT: Series B	A: 145000000 MR: - FA: $145 million FAN: 145000000	D: 2023-08-03 FD: 2023-08-03	11 investors
8	RT: Series A T: - FT: Series A	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2020-01-13 FD: 2020-01-13	3 investors

Public Offering Latest

2025-12-17

$100.0M

4 investors (Pro only)

Public Offering 2025-12-15

$100.0M

Debt 2025-11-03

$150.0M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Peter A. Merkel

Chief of Rheumatology and Professor of Medicine and Epidemiology at the University of Pennsylvania

I

Ignacio Sanz

Mason I. Lowance Professor of Medicine and Pediatrics, Chief of the Division of Rheumatology, and Director of the Lowance Center for Human Immunology at Emory University

G

Georg Schett

Professor and Head of Department of Internal Medicine 3 at Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

W

Warner Biddle

Chief Executive Officer

C

Cara Bauer

Chief Human Resources Officer

D

Dominic Borie

Strategic Advisor

View 15 more team members with Pro

Unlock Full Team Directory

Recent News